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ABSTRACT 
Methylene blue (MB) has many uses within both microbiology and pharmacology. MB can treat 
disorders such as methemoglobinemia, malaria, Alzheimer’s disease, and certain forms of 
cancer. MB is also useful for molecular imaging due to its off-on fluorescent capabilities. MB 
derivatives with a urea bond at the 10-N position have been cleavable by triggers such as light. 
However, I was interested in sensitivity to reactive oxygen species (ROS). In this study, I wanted 
to determine if the MB derivative MB-EA exhibited sensitivity to ROS. MB-EA was exposed to 
varying concentrations of hydrogen peroxide and MB release was measured. I concluded that 
MB-EA is increasingly sensitive to increasing concentrations of hydrogen peroxide, and exhibits 
sensitivity to ROS. This could allow for new MB therapeutics to be administered in diseases that 
produce ROS.   
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Background 
Methylene blue (MB) is a synthetic dye with extensive pharmacological activity and 
many biomedical applications. Its chemical structure can be seen in Figure 1.  
 
 
Figure 1. Structure of Methylene Blue 
 
 MB is FDA approved for the treatment of acquired methemoglobinemia. Methemoglobinemia 
is characterized by hemoglobin being unable to carry oxygen due to the ferrous component of 
the heme molecule being oxidized to a ferric state. MB corrects this issue by reacting within the 
red blood cell to reduce to leuco-methylene blue (L-MB), which is then able to reduce the ferric 
iron (Fe3+) back to oxygen carrying ferrous iron (Fe2+). 1 MB has also proven to be an effective 
antimalarial therapy. MB has shown substantial antimalarial activity against all forms of malaria 
in various endemic areas, and when combined with other antimalarial agents, it has shown 
activity against falciparum malaria in Africa. MB seems to act slowly against P. falciparum when 
administered alone; however, when administered with artemisinin the combination rapidly 
cleared parasites and decreased transmission from mosquitos.  MB as an antimalarial 
therapeutic has become more researched as of late as P. falciparum is becoming more resistant 
to many common drug therapies such as chloroquine. 2 MB has also demonstrated that it can 
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be useful for slowing the progression of Alzheimer’s disease (AD). MB has an inhibitory effect 
on the cGMP pathway, and it also affects many cellular and molecular events that are closely 
associated with the progression of AD, such as attenuating formations of amyloid plaques and 
neurofibrillary tangles and partially repairing impairments in mitochondrial function and cellular 
metabolism. MB also affects many neurotransmitter systems that are believed to play 
important roles in the pathogenesis of AD.3 
 MB has also shown great results as a photodynamic therapeutic. Photodynamic therapy 
(PDT) involves a photosensitizer that is localized in the target tissue being illuminated with 
visible light. PDT has been used with positive results in treating several forms of cancer, and 
PDT provides many advantages over other cancer therapies. PDT works on almost all types of 
cancers, and PDT can be repeated several times if necessary because there are no cumulative 
toxic effects. Also, PDT is usually an outpatient procedure, and it can also be used for treating 
elderly patients or patients who are too sick for surgery due to its lower risk profile. Tardivo et 
al. conducted a study in which they treated several superficial tumors with MB and light and 
found promising results. Patients with basal cell carcinoma, metastatic melanoma, and Kaposi’s 
sarcoma were treated, and a majority of patients experienced a complete response. PDT using 
MB has also shown good anti-bacterial activity. MB has shown photobacteriocidal effects on 
Enterococcus ssp as well as Staphylococcus aureus. MB’s use as an anti-bacterial agent could 
become more prominent as bacterial resistance to other therapies increases.4  
 MB is also useful for molecular imaging due to its off-on fluorescence. When MB is 
chemically modified at the 10-N position, no fluorescence is observed. However, once the 
conjugated portion is cleaved from the 10-N position, MB’s fluorescence is turned back on.5  
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This has proven to be beneficial for imaging and treatment skin-related diseases such as 
bacterial infections and skin cancer. MB’s off-on fluorescence has also been used to create a 
near-infrared light (NIR) fluorescent probe for the detection of nitroreductase (NTR). This probe 
was created in a study conducted by Bae et al. by conjugating a p-nitrobenzyl group through a 
carbamate bond to MB at the nitrogen of the phenothiazine ring. In the presence of NTR, this p-
nitrobenzyl group will be cleaved and MB’s fluorescence will be turned on. This NTR induced 
activation renders p-nitrobenzyl methylene blue (p-NBMB) a satisfactory imaging sensor for the 
detection of bacteria expressing NTR.6  
Methods 
In a few of the aforementioned applications and therapies of MB, reactive oxygen 
species (ROS) were addressed as a possible variable in experimental or clinical outcomes. The 
goal of my study was to determine ROS sensitivity of the MB derivative MB-ethanolamine (MB-
EA). MB-EA was synthesized from MB-nitrophenyl (MB-NP), and MB-NP was derived from L-
MB, which is easily generated from MB. To provide a little more detail, methylene blue 
monohydrate (1,200 mg, 3.2 mmol) was dissolved in 100 ml of deionized water. Toluene (150 
ml) was added to the solution of MB followed by nitrogen flushing. After a constant nitrogen 
flow was established, sodium dithionate (1,116 mg, 6.4 mmol) followed by sodium carbonate 
anhydrous (680 mg, 6.4 mmol) was added to the reaction mixture while stirring at 50oC. After 
15 min of vigorous stirring, the reaction mixture faded from yellow and both phases became 
clear, indicating that L-MB was transferred into toluene phase. This L-MB is then used to form 
MB-NP. Toluene phase containing L-MB was transferred into a nitrogen-discharged flask 
containing anhydrous sodium sulfate for drying under a nitrogen atmosphere via dropwise 
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addition over 10 min. Resultant anhydrous L-MB solution in toluene was transferred into a 
solution of  each chloroformate solution dissolved in 10 ml of toluene maintained in an ice 
bath; 4-nitrophenyl chloroformate (1,286 mg, 6.4 mmol) for MB-NP. Upon completion of 
transferring L-MB into each chloroformate solution, triethylamine (TEA) (1,692 µl, 12.8 mmol) 
was added. The reaction was proceeded overnight at room temperature. Then, reaction 
mixture was collected after rinsing three times with each of the following solutions using a 
separatory funnel: saturated sodium bicarbonate, 0.01N hydrochloric acid solution, and brine. 
The obtained organic phase was dried, evaporated under reduced pressure and recrystallized in 
acetonitrile 2 times and yielded a bright orange solid crystal of MB-NP. MB-NP (450 mg, 1.0 
mmol) was dissolved in anhydrous THF and added dropwise into ethanolamine (620 mg, 11.11 
mmol). Later TEA (259 µl, 2.0 mmol) in anhydrous THF solution was added to the solution. The 
reaction mixture was protected from light during reaction and refluxed at 60oC for 24 hours. 
Upon completion of the reaction, the mixture was collected, evaporated under reduce 
pressure, dissolved in dichloromethane and washed three times with each of the following 
solutions: saturated sodium bicarbonate, and water. The obtained organic phase was dried, 
evaporated under reduced pressure and subjected to flash column chromatography using 
hexane:ethylacetate 1:1, and later 100% acetone. The eluted solution was evaporated under 
reduced pressure to yield a light blue powder of MB-EA. Scheme 1 shows the process from MB 
to L-MB and then to MB-NP and other carbamate bond containing derivatives, while scheme 2 
shows the production of MB-EA and other urea bond containing MB derivatives from MB-NP. 
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Scheme S1. Synthetic scheme of carbamate bond-containing MB derivatives MB-NP. Reagents 
and conditions: (1) MB, sodium dithionate, sodium carbonate, water/toluene, 50oC, 1 h; (2), (3) 
and (4): leuco methylene blue, 4-nitrophenyl chloroformate (2), triethylamine (TEA), dry 
toluene, 2-4oC 1h, room temperature (RT) 24 h. The synthesis of MB-NB has been previously 
described1. 
 
Scheme S2. Synthetic scheme of urea bond-containing MB derivatives. Reagents and 
conditions: (1) MB-NP, primaquine (PQ) base, anhydrous tetrahydrofuran (THF), TEA, 60oC 
reflux 24 h. (2) MB-NP, excess ethanolamine (EA), anhydrous THF, TEA, 60oC reflux overnight.  
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To observe ROS sensitivity of MB-EA, I incubated four vials containing MB-EA 4 micrograms/ml 
and introduced varying concentrations of hydrogen peroxide (H2O2), a reactive oxygen species, 
to each vial. Hydrogen peroxide was chosen due to its increased stability over other ROS. The 
vials were given H2O2 concentrations of 0 micromolar (control), 100 micromolar, 1,000 
micromolar, and 10,000 micromolar.  Each vial was then wrapped in aluminum foil and placed 
inside of a refrigerator. This eliminated all exposure to light and prevented any cleavage that 
could have occurred at room temperature. The vials were then checked daily for four days and 
the fluorescence of each vial was measured using a fluorometer. Fluorescence measurements 
were performed using a LC500 Perkin Elmer fluorescence spectrophotometer at 660 nm 
excitation wavelength, 600 to 800 nm emission wavelength, 10nm excitation slit, and 10 nm 
emission slit. Exactly 1 ml of the tested solution was loaded into the fluorescence cell and 
sealed with a paraffin film to prevent solvent evaporation during the irradiation process. The 
vials were checked and the fluorescence was measured at the same time each day so that there 
was a uniform 24 hours between each measurement. After being measured, the vials were 
wrapped in foil again and returned to the refrigerator until the next measurement.  
Results 
 I hypothesized that as the concentration of H2O2 increased, the amount of MB released 
would also increase. This result is due to H2O2 cleaving MB-EA, thus releasing MB from the 
bound ethanolamine group and restoring its fluorescence. The proposed off- on cleavage of 
MB-EA is demonstrated in Figure 2.  
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The data gathered from the fluorometer was organized and formatted into a graph (Figure 3) 
that displays MB released over time. The graph demonstrates that as the H2O2 concentration 
was increased, the amount of MB released was also increased. The vial with the highest 
concentration of H2O2, 10,000 micromolar, exhibited 100% MB release after 3 days. The 1,000 
micromolar and 100 micromolar vials both showed increases in MB released each day; 
however, neither concentration produced full MB release buy the end of the four days. The 
1,000 micromolar H2O2 vial showed greater MB release than the 100 micromolar H2O2 vial. The 
control vial containing no H2O2 did not release any MB during the four days. The data shows 
that MB-EA is relatively stable in the absence of H2O2, but demonstrates significant sensitivity 
to increasing concentrations of H2O2. To further demonstrates that MB-EA is cleaved to release 
fluorescent MB, MB-EA was incubated with H2O2 1,000 micromolar for 10 days. The fluorescent 
intensity of the cleaved MB over time is displayed in Figure 4. 
Fluorescence off Fluorescence on 
Figure 2. MB-EA off-on fluorescence 
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Figure 3. MB release over time with varying H2O2 concentrations 
 
Figure 4. MB fluorescence overlay 
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Discussion 
In this study, MB-EA was incubated with varying concentrations of H2O2, a reactive oxygen 
species, in order to evaluate the sensitivity of MB-EA to ROS. Upon addition of H2O2 to MB-EA 
solution, MB-EA was cleaved and MB was released. This result has clinical and experimental 
implications. Many disease states, such as cancer, place the body under oxidative stress, and 
this causes the production of ROS. The cleavage of MB derivatives by ROS can allow for the 
binding of other drugs or imaging agents to MB to be cleaved by interacting with ROS in 
diseased tissues. From a research perspective, studies in which researchers are trying to cleave 
MB from another bound molecule by any method other than ROS must be sure that the 
environment is devoid of ROS in order to obtain accurate results. If ROS is present, then it will 
be quite difficult to determine if MB was cleaved by their desired mechanism or if MB was 
cleaved by ROS. Researchers and clinicians should always be mindful of ROS when dealing with 
MB derivatives. One limitation of the study is that only one ROS and one MB derivative were 
used in the experiment. This provided very specific data, and more research would need to be 
done to expand the data to other types of ROS and MB derivatives. Another limitation is that 
ROS concentrations in diseased tissues were not gathered in this study, and these would be 
useful for clinical applications. There are a few directions for future research. First, more 
research should be conducted to test MB sensitivity to other ROS, such as hydroxy radical, 
superoxide, and nitric oxide, in order to find specificity. Research should also be done to test 
the stability of MB derivatives in different biological fluids and at different pH levels. This will 
provide data that would allow researchers to predict how MB derivatives would act in different 
areas of the body. Lastly, future research should also focus on possible conjugation of MB 
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derivatives with drug molecules or imaging probes to determine if this could provide an 
improvement over other therapies and diagnostics.  
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